Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
27/04/2026 12:05
April 27 (Reuters) - Intellia Therapeutics NTLA.O said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study. (Reporting by Kunal Das; Editing by Vijay Kishore) ((Kunal.Das2@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)